Activating mutations of full‐length ALK are found in 8%−12% of neuroblastomas, including familial neuroblastoma, and ALK amplification is found in 2%−3% of neuroblastomas, increasing the risk of relapse.5 This evidence concerns the gene ALK and neuroblastoma.